Effect of the Dual 5α-Reductase Inhibitor Dutasteride on Markers of Tumor Regression in Prostate Cancer
March 2005
in “
The Journal of urology/The journal of urology
”
TLDR Dutasteride may help shrink prostate cancer tumors.
The document discussed the effects of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. It was a correction to a previous study by G.L. Andriole and colleagues. The study aimed to evaluate the impact of dutasteride on prostate cancer by examining changes in tumor markers. The findings suggested that dutasteride could influence tumor regression, providing insights into its potential therapeutic role in managing prostate cancer. However, specific details on the study's methodology, sample size, and statistical significance were not provided in the summary.